Mpox Reaches Eastern Mediterranean as Cancer Vaccines and Antibiotics Advance

An unusual week in global health: a new infectious disease front opens in the eastern Mediterranean while major clinical milestones arrive in cancer immunotherapy, antimicrobial resistance, ageing biology, and preventive care.

Wednesday, 24 September: ECDC Raises Mpox Clade Ib Alert for Eastern Mediterranean

The European Centre for Disease Prevention and Control issued a rapid risk assessment on Wednesday, warning that mpox clade Ib — the more transmissible strain first detected in the Democratic Republic of Congo in 2023 — has been confirmed in four eastern Mediterranean countries, with travel-linked cases identified in Greece and potential exposures reported in Cyprus. Clade Ib differs from the clade IIb strain responsible for the 2022 global outbreak in that it spreads more readily through close household contact and carries a higher case-fatality rate in unvaccinated individuals.

The WHO Regional Office for Europe notes that JYNNEOS (modified vaccinia Ankara) vaccine stocks are adequate across EU member states and recommends vaccination for people with multiple sexual partners and for healthcare workers in high-risk settings. Cyprus's Ministry of Health has activated its infectious disease rapid-response protocol and is asking clinicians to consider mpox in patients presenting with unexplained rash and fever who have a recent travel history to Sub-Saharan Africa or a confirmed contact with a case. As of Wednesday, no locally acquired Cypriot cases had been confirmed.

Wednesday, 24 September: Personalised mRNA Cancer Vaccine Extends Survival in Pancreatic Cancer Trial

Results published in The New England Journal of Medicine show that autogene cevumeran — an individualised mRNA neoantigen vaccine co-developed by BioNTech and Genentech — extended median progression-free survival by 6.1 months compared with adjuvant chemotherapy alone in patients with resected pancreatic ductal adenocarcinoma. The Phase 2b trial enrolled 157 patients across 18 centres.

Each vaccine is engineered within six weeks of surgery by sequencing the patient's tumour to identify up to 20 mutation-derived neoantigens unique to that individual. Patients whose tumours generated a robust T-cell response — approximately 48% of those treated — showed a threefold increase in two-year recurrence-free survival. Pancreatic cancer has a five-year survival rate below 15%, making even a Phase 2b signal meaningful. The authors caution that a Phase 3 confirmatory trial, planned to begin enrolment in early 2027, is required before this approach can be considered for regulatory approval.

Thursday, 25 September: FDA Approves Cefepime-Taniborbactam for Carbapenem-Resistant Infections

The US Food and Drug Administration granted full approval to cefepime-taniborbactam (Exblifep, Venatorx Pharmaceuticals) for hospital-acquired and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Gram-negative organisms, including KPC- and metallo-β-lactamase-producing strains. The approval rests on the CERTAIN-1 Phase 3 trial, in which the drug achieved a clinical cure rate of 68.2% versus 52.7% for the comparator (p < 0.001).

Carbapenem-resistant organisms cause an estimated 35,000 deaths per year in the EU alone; the WHO classifies them as a Priority 1 "critical" pathogen. The European Medicines Agency is expected to consider a rolling review application before the end of 2026. For Mediterranean and eastern European hospitals — where KPC-producing Klebsiella pneumoniae has been endemic in intensive care units for more than a decade — this represents a meaningful addition to a therapeutic arsenal that has long been outpaced by resistance.

Thursday, 25 September: Senolytic Drug Improves Physical Function in Frail Older Adults

A Phase 2 placebo-controlled trial published in Nature Medicine shows that a six-month course of navitoclax (ABT-263) — a drug that selectively eliminates senescent cells — improved six-minute walk distance by 38 metres on average compared with a 4-metre decline in the placebo group (p = 0.006). The 112-person trial enrolled adults aged 65–80 with documented physical frailty and elevated plasma markers of senescent cell burden.

Senolytics aim to clear the body's accumulation of malfunctioning, non-dividing cells that secrete pro-inflammatory signals associated with age-related decline. Navitoclax's main safety concern — reduced platelet counts due to BCL-2 inhibition — was managed through dose optimisation without any grade 3 or higher bleeding events. An editorial in Nature Medicine described the results as "the most compelling human evidence to date for the senescence hypothesis of ageing." Phase 3 trials are still required, and the drug is not available outside clinical studies at this stage.

Thursday, 25 September: WHO Cervical Cancer Report — Europe Near Target, Eastern Mediterranean Gaps Persist

The World Health Organization released its 2026 progress update on the global cervical cancer elimination strategy, which sets a 2030 target of 90% HPV vaccination coverage among girls aged 9–14. Twenty-two EU member states have now exceeded that threshold. Separately, the European Medicines Agency extended the Gardasil 9 (9-valent HPV vaccine) marketing authorisation to include women aged up to 50, based on immunogenicity and long-term safety evidence showing durable protection comparable to that in younger age groups.

The report flags persistent gaps in the eastern Mediterranean: several Balkan states and parts of the Levant have HPV vaccination coverage below 40%. Cyprus recorded 81% — close to but still below target — with the Ministry of Health citing school nurse capacity as a barrier. WHO's regional advisor called on health ministries to embed HPV vaccination into routine adolescent primary-care visits. Cervical cancer is almost entirely preventable; closing regional vaccination gaps would eliminate most future cases.

Tuesday, 23 September: Large RCT Finds High-Dose Vitamin D Does Not Prevent Respiratory Infections in Non-Deficient Adults

A multicentre, double-blind, placebo-controlled trial published in The BMJ and co-funded by the National Institute for Health Research enrolled 6,200 adults across seven countries and found that 4,000 IU/day of vitamin D3 for 12 months did not reduce the incidence or severity of acute respiratory tract infections in people whose baseline serum 25-hydroxyvitamin D was already in the sufficient range (≥ 30 nmol/L).

The finding clarifies, but does not overturn, earlier meta-analyses suggesting a modest protective effect from vitamin D supplementation. That benefit appears confined to people who are genuinely deficient: participants in this trial with baseline levels below 30 nmol/L who received the supplement showed a 19% reduction in infection risk (95% CI 6–30%), consistent with prior evidence. A BMJ editorial advises that correcting documented deficiency remains worthwhile, but routine high-dose supplementation in the absence of deficiency is unlikely to reduce respiratory illness.

---

This article is a journalistic summary of published research and public-health guidance. It is not medical advice. Readers should consult a qualified healthcare professional before making any change to their treatment, medication, or preventive health regimen.